Blatta Orientalis 2 X Globules ; Granules ; Liquid is a Health Canada–registered human drug (DIN 02234353) held by Dolisos Canada Inc., containing Blatta Orientalis. Health Canada lists its status as Cancelled Post Market (status date 20 Apr 2006). Nexara Health has matched 13 registrations of Blatta Orientalis across 1 other regulated market.
Health Canada registration
| DIN | 02234353 |
|---|---|
| Brand name | Blatta Orientalis |
| Active ingredient | Blatta Orientalis |
| Strength | 2 X |
| Dosage form | Globules ; Granules ; Liquid |
| Route | Oral |
| Company | Dolisos Canada Inc. |
| Status | Cancelled Post Market — 20 Apr 2006 |
| Class | Human |
| ATC | |
| AHFS | 92:02.00* ; See footnote |
| Regulator record | Health Canada DPD entry · Product monograph |
Blatta Orientalis registered in other markets
13 registrations of the same molecule in 1 national registry outside Canada (first 8 shown, exact strength and form first). Each row is taken from the regulator's own published list; status is shown as the registry reports it.
| Country | Product | Marketing authorisation holder | Strength | Form | Status | Registry |
|---|---|---|---|---|---|---|
| United States | Blatta orientalis | Boiron | Pellet | listed | FDA NDC | |
| United States | Blatta orientalis | Boiron | Pellet | listed | FDA NDC | |
| United States | Blatta orientalis | Boiron | Pellet | listed | FDA NDC | |
| United States | Blatta orientalis | Boiron | Pellet | listed | FDA NDC | |
| United States | Blatta orientalis | Boiron | Pellet | listed | FDA NDC | |
| United States | Blatta Orientalis | Hahnemann Laboratories, INC. | Pellet | listed | FDA NDC | |
| United States | Blatta Orientalis | Hahnemann Laboratories, INC. | Pellet | listed | FDA NDC | |
| United States | Blatta Orientalis | Hahnemann Laboratories, INC. | Pellet | listed | FDA NDC |
See every manufacturer of Blatta Orientalis worldwide →
Sourcing through Nexara Health
Nexara Health is a Health Canada–licensed wholesaler (DEL #3-002896) in Winnipeg. This DIN is not currently marketed in Canada. The registrations above show which regulated markets hold an equivalent presentation that can be sourced for clinical comparator use or on a named-patient basis under Health Canada's Special Access Programme. Request a quote or read how named-patient and foreign-pack supply works in Canada.
Frequently asked questions
Is Blatta Orientalis (DIN 02234353) marketed in Canada?
No. Health Canada lists DIN 02234353 as Cancelled Post Market as of 20 Apr 2006.
Who holds the Canadian licence for this product?
Dolisos Canada Inc. is the company of record in the Health Canada Drug Product Database.
Is Blatta Orientalis registered outside Canada?
Yes — Nexara Health has matched 13 registrations in 1 other market (see the table above).
Where does this data come from?
Health Canada Drug Product Database (DPD), DIN 02234353, status date 2006-04-20; national medicine registries: FDA NDC. Nexara Health re-checks these sources weekly and shows the last verification date at the top of the page.
Source: Health Canada Drug Product Database (DPD), DIN 02234353, status date 2006-04-20; national medicine registries: FDA NDC.
Health Canada Drug Product Database (DPD), DIN 02234353, status date 2006-04-20; national medicine registries: FDA NDC. Last reviewed 2026-09-17. Nexara Health is a licensed wholesaler and supplies licensed entities only; consumer orders are routed to a partner pharmacy.